Next Article in Journal
Vertical Transmission of SARS-CoV-2: A Systematic Review of Systematic Reviews
Previous Article in Journal
A Reverse Transcription Recombinase-Aided Amplification Method for Rapid and Point-of-Care Detection of SARS-CoV-2, including Variants
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 13
Issue 9
10.3390/v13091876
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Lymphopenia Caused by Virus Infections and the Mechanisms Beyond

by
Zijing Guo
1,2,
Zhidong Zhang
2,
Meera Prajapati
2,3 and
Yanmin Li
2,*
1
State Key Laboratory on Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730030, China
2
College of Animal Husbandry and Veterinary Medicine, Southwest Minzu University, Chengdu 610041, China
3
National Animal Health Research Centre, Nepal Agricultural Research Council, Lalitpur 44700, Nepal
*
Author to whom correspondence should be addressed.
Viruses 2021, 13(9), 1876; https://0-doi-org.brum.beds.ac.uk/10.3390/v13091876
Submission received: 28 July 2021 / Revised: 14 September 2021 / Accepted: 18 September 2021 / Published: 20 September 2021
(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
Browse Figure
Review Reports Versions Notes

Abstract

:
Viral infections can give rise to a systemic decrease in the total number of lymphocytes in the blood, referred to as lymphopenia. Lymphopenia may affect the host adaptive immune responses and impact the clinical course of acute viral infections. Detailed knowledge on how viruses induce lymphopenia would provide valuable information into the pathogenesis of viral infections and potential therapeutic targeting. In this review, the current progress of viruses-induced lymphopenia is summarized and the potential mechanisms and factors involved are discussed.

1. Introduction

Lymphocytes are important elements of the immune system. They are categorized into T lymphocytes (T cells), B lymphocytes (B cells) and natural killer (NK) cells based on their migration, surface makers and biological functions [1]. Lymphopenia is the condition in which there is an abnormal reduced number of lymphocytes in the peripheral blood. It is diagnosed when a total lymphocyte number is lower than normal for a particular age group (for instance, less than 1000 cells/μL in older children and adults) [2,3,4]. Such obvious reduction in blood lymphocytes count occurs due to viral infections [5], chemical and physical lympho-depleting agents [6], autoimmune-related systemic diseases [7], genetic factors [8], cancers [9], sepsis [10] and other severe injuries [11]. Generally, most viruses lead to relative lymphocytosis, while only a few viruses causing severe disease could result in lymphopenia, such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [12], ebola virus (EBOV) [13] and human immunodeficiency virus (HIV) [14]. Although numerous studies were attempted to reveal the causes of lymphopenia during viral infections, the mechanisms underlying it is still unclear. It is believed that the mechanism underlying lymphocyte depletion is more complicated as different factors or mechanisms are involved during the infection caused by different viruses. In this review, the current progress of the lymphopenia induced by viral infections with emphasis on RNA viruses is summarized and the mechanism and factors involved during various virus infection-mediated lymphopenia are discussed.

2. Mechanisms of Lymphopenia Associated with Viral Infections

Lymphopenia was observed in patients and animals infected with different viruses which belong to different viral families and thus exhibit varied morphology, physicochemical and physical properties, genome organization and replication and antigenicity. However, infections by most of these viruses could cause serious illness or even death and it was found that lymphopenia is associated with disease severity. Despite numerous studies on causes of lymphopenia during viral infections, the mechanisms underlying still remain vague. The proposed mechanisms for the observed lymphopenia are summarized as follows (Table 1, Figure 1). Unlike the RNA viruses mentioned below, the mechanism of lymphopenia caused by DNA virus infections is also still unknown. So far, the underlying factors and molecular mechanisms of lymphopenia caused by most DNA viruses have rarely been reported which needs to be addressed in the future.

2.1. Cell Death

Lymphocyte death plays a critical role in lymphopenia caused by many viral infections (Table 1). Apoptosis, pyroptosis, autophagy, virus-specific CD8+ cytotoxic T lymphocyte (CTL) dependent killing and antibody-dependent cell-mediated cytotoxicity (ADCC) were reported to be involved in lymphopenia. Among them, apoptosis was thought to be a major pathway involved in lymphopenia [39,62,68].
Apoptosis: Apoptosis is a tightly regulated form of cell death that is vital in both embryo implantation and development and turnover of tissues during maturation. Lymphocyte’s apoptosis has been widely reported during viral infections, such as SARS-CoV-2 [15], HIV [39] and IAV [62]. Until now, the mechanism responsible for lymphocytes apoptosis is not fully understood. Although apoptosis of lymphocytes could be induced due to direct infection of lymphocytes with the viruses, such as MERS-CoV [23,24], HIV [111] and MV [67], the number of such virus-infected cells was very few to match with the reduced levels of lymphocytes observed during viral infections. Some studies even suggested that lymphocytes could not be infected by other viruses, such as SARS-CoV-2 [15] and FMDV serotype O/A [81,84]. Thus, apoptosis of bystander cells is considered as a major mechanism for lymphocytes depletion induced by viral infections [39,112,113]. There were many factors reported to trigger apoptosis in uninfected bystander lymphocytes, including the activation of apoptosis related-receptors (Fas/FasL) [61], the interaction between viral protein and host cellular receptors [114] and cytokines (TNF-α) [115,116].
Activation-induced cell death (AICD): The interaction between FasL and Fas is usually engaged in AICD, which enhances apoptosis in T lymphocytes previously stimulated to cause contraction of T cells when T lymphocytes are re-activated via T cell receptors (TCR) [117,118,119]. AICD in peripheral T cells is often caused by the induction of expression of the death ligand, Fas ligand (CD95 ligand, FasL). During SARS-CoV-2-, RSV- and CDV- infection, the Fas expression was negatively correlated to CD4+ T lymphocyte count in blood, indicating that the increased expression of Fas was involved in lymphopenia through apoptosis of bystander T cells [70,71,76,119].
Dendritic cell (DC)-dependent killing of lymphocytes: Previous studies showed that a depletion of CD8+ T cell responses in lethal H2N2 influenza virus infection was mediated by lymph node resident DCs, especially plasmacytoid dendritic cells (pDCs) that express FasL and drive FasL–Fas induced T cell apoptosis in a dose-dependent manner [120,121]. Similarly, H5N1 infection in mice enhanced FasL expression on pDCs, resulting in apoptosis of influenza-specific CD8+ T cells via a Fas–FasL-mediated pathway [61,121]. In addition, HIV-infected DCs induced CD8+ T cell apoptosis by up-regulating TNF-α in infected DCs and activation of the caspase 8-dependent pathway in CD8+ T cells [122].
Pyroptosis: Pyroptosis is a programmed cell death with high inflammation. The dying cell releases its cytoplasmic contents, including inflammatory cytokines [123]. These cytokines in turn induce pyroptosis in other T cells, which also contribute to T cells depletion. IL-1β, a marker of pyroptosis, was increased during SARS-CoV-2 and HIV infection, indicating that lymphocytes were undergoing pyroptosis. During CSFV infection, pyroptosis was also determined in peripheral lymphoid organs by TdT-mediated dUTP nick-end labeling (TUNEL) and detection of pyroptosis related genes (such as p10 subunit, caspase-1 and IL-1β) [87]. It is necessary to further investigate how these viral infections induce lymphocytes pyroptosis.
Autophagy: Autophagy is an important component of anti-viral defense in host cells. During autophagy, the viruses are initially pinned down into autophagosomes and then delivered to lysosomes for degradation [124]. Until now, autophagy was only reported in patients infected with SARS-CoV-2, HIV and EBOV. In COVID-19 patients, the upregulated expressions of autophagy-associated genes have been observed in PBMCs, which indicates that these cells may undergo autophagy and ultimately cell death [15]. In HIV infected patients, autophagy mediated by HIV gp41 protein was reported in the uninfected CD4+ T cells [41]. In EVD patients, autophagy was induced in T cells through activating endoplasmic reticulum (ER) stress related signaling pathways [13].
Virus-specific CD8+CTL dependent killing: The CTL remove the virus-infected lymphocytes through interaction of FasL with Fas and TNF-related apoptosis-inducing ligand (TRAIL–TRAILR). CTL induce apoptosis of targeted cells by perforin and granzymes and by the death ligand, CD95 ligand (CD95L) [125]. Although a small proportion of lymphocytes infected with SARS-CoV-2 could be eliminated by CTL-dependent killing [126], it is believed that CTLs are not likely to be involved in lymphocytes death due to the lack of infection. Thus, CD8+CTL dependent killing is more likely to occur in lymphocytes infected with MERS-CoV, HIV, CDV, etc.
ADCC: Antibodies specific to the viral surface antigens are able to block attachment of a virus to its target cell. However, virus-infected cells could be also bound by the antibodies against the virus by recognition of viral antigens presented on the cells. There are a variety of mechanisms involved in killing the antibody-coated cells infected with the virus, such as phagocytosis, activation of complements and ADCC [127]. It is noted that more severe lymphopenia and higher titers of IgG and IgM against the virus were observed in patients, who had severe COVID-19 in comparison with patients having moderate and mild severity [16].

2.2. Involvement of Cytokines, Chemokines and Growth Factors

Upregulated expression of cytokines, chemokines and growth factors was commonly observed in patients and animals with lymphopenia induced by viral infection, including IL-2, IL-6, IL-12, IL-18, IL-1β, IFN-γ, CCL2/MCP-1, CXCL1, CXCL8/IL-8, CCL3/MIP-1-α, CCL7/MCP-3, CXCL10/IP-10 and CXCL9/MIG [17,53,128]. It is noted that the kinds of elevated cytokines, chemokines and growth factors caused by varied viral infections is different, i.e., the infections of SARS-CoV, MERS-CoV, HIV and FMDV could trigger higher levels of IFNs. Conversely, the infection of SARS-CoV-2 did not induce any IFN expression at all assessment time points [129]. Among cytokines, chemokines and growth factors reported, IL-6 is the most common cytokine which was upregulated during infections with many viruses including SARS-CoV-2, SARS-CoV, HIV, EBOV, IAV, RSV, CSFV and HNoV. Different cytokines induced lymphopenia through different mechanisms; it is believed that the synergic action of cytokines, chemokines and growth factors plays a vital role in induction of lymphopenia during viral infection, although the molecular mechanism beyond remains unclear.
IL-6, produced rapidly in response to infection and tissue damage, promotes host defense by stimulating the acute phase responses or immune response. However, the excessive release of IL-6 plays a pathological role in chronic infection and inflammation [130]. Notably, IL-6 could inhibit lymphopoiesis by directly impairing hematopoietic stem cells [131] and STAT-3 activation [132]. Recent studies found that T cells counts were negatively correlated to IL-6, IL-10 and TNF-α concentration in serum, which indicated that these cytokines may be involved in T cells depletion in COVID-19 patients [18,19]. The drugs blocking IL-6 receptor (IL-6R), such as tocilizumab, sarilumab and siltuximab, have been considered as a treatment strategy for severe COVID-19 patients with high IL-6 levels [133]. Importantly, lymphocytes count was recovered after treatment with IL-6R [134].
IL-10 as an anti-inflammatory cytokine exhibits a dual role in promoting pathogen persistence [135] and limiting immune pathology [136]. A previous study found that IL-10 was able to suppress proliferation of T cells [137]. Study on chronic infection in animal models showed that blocking IL-10 signaling could successfully prevent T cell exhaustion [138]. In addition, T cell apoptosis could be induced by IL-10 produced by CD9+ regulatory B cells.
TNF-α is also a pro-inflammatory cytokine and could induce cell apoptosis through interacting with its receptor TNFR1 [115]. Previous studies suggested that TNF-α produced by macrophages infected with ASFV leads to apoptosis in bystander T lymphocytes [116]. Similarly, apoptosis was observed earlier in lymphocytes from FIP cats [34], and apoptosis was further reported to be caused by TNF-α or other potential cytokines, instead of viral direct infection [33,35].
Interferons (IFNs) were originally identified as a humoral factor that confer an antiviral state on cells [139], but now, it has also been found to regulate lymphocyte recirculation and cause transient blood lymphopenia [140]. During IAV, CSFV and FMDV infection, the onset of lymphopenia was consistent with the IFN-α responses, and all animals with a high IFN-α level in serum showed severe depletion of lymphocytes [63,85,88]. IFN-γ has a critical part in bridging the innate and adaptive immunity, but IFN-γ has been reported to promote apoptosis. It has been proposed that IFN-γ may promote apoptosis of the bystander T cell following EBOV infection [141]
In addition to IL-6, IL-10, TNF-α and IFNs, other cytokines, chemokines and growth factors were also involved in lymphopenia. For instance, IL-15 has been reported to affect proliferation and differentiation of lymphocytes [142], MCP-1 and CXCL13 were reported to be involved in the migration of lymphocytes [42,143,144].

2.3. Inhibition of Lymphopoiesis

There are many ways to inhibit lymphopoiesis during viral infection. First, the damage of lymphoid organs (thymus, lymph nodes, bone marrow, liver and lung) was observed in severe illness caused by SARS-CoV-2, CDV and CSFV with lymphopenia, which has negative impacts on the survival, production and function of lymphocytes [87,89,145,146,147]. The thymus, an important lymphoid organ, is responsible for the generation and maturation of T cells. However, thymic dysfunction and involution have been observed in patients infected with HIV [148], SARS-CoV-2 [149], MV [150] and H1N1 [151], which were triggered by direct thymocyte killing. Thymus suppression affects lymphopoiesis and the survival of lymphocytes. Second, the development of haematopoietic precursor cells (HPC) was suppressed through viral direct infection and the synergic action of cytokines, chemokines and growth factors. Previous studies postulated that SARS-CoV-2 and CSFV may directly infect haematopoietic stem cells (HSC) and thus induce cell death [20,90]. In addition, hyperproinflammatory cytokines are produced by activated immune cells that affect the process of lymphopoiesis in the bone marrow. Studies have suggested that the reciprocal dynamics of lymphocyte and neutrophil populations in the bone marrow are consistent with cellular interaction and competition [152]. However, inflammation could regulate the balance of granulopoiesis and lymphopoiesis in bone marrow by suppressing common proinflammatory cytokines and growth factors (TNF-α, IL-1β, CXCL12, IL-6, etc) that affect lymphopoiesis more strongly than granulopoiesis [152,153]. TNF-α treatment results in a reduction in lymphocyte progenitor populations in the bone marrow, while IL-1β elicits increased granulocyte precursors [154]. Moreover, CXCR4-CXCL12 interactions facilitate cytokine-mediated regulation of B cell and myeloid cell retention in the bone marrow [154]. IL-6 has been reported to abort lymphopoiesis and elevate production of myeloid cells by expression of Id1 transcription factor, which is known to inhibit lymphopoiesis and elevate myelopoiesis, and its expression was dependent on MAPK [131]. Although the cellular source of these cytokines was not determined during many virus infections (e.g., the cellular source of elevated IL-6 in COVID-19 patients [155]), the synergic action of these proinflammatory cytokines may inhibit lymphopoiesis in the bone marrow. Lastly, inhibition of the lymphocyte activation and proliferation by the loss of the antigen-presenting ability would also promote lymphopenia associated with viral infections. For example, DCs from healthy and convalescent COVID-19 patients could stimulate T cell proliferation, but none of the DCs derived from acute COVID-19 patients showed similar activity, which indicated that DCs from acute patients showed functional impairment in both maturation and T cell activation [21]. Similarly, DCs infected with EBOV and IAV inhibit the ability of antigen presentation and affect the capacity of activating T cells thereby limiting the ability to pass survival signals to T cells [54,64,156]. Further studies revealed that the activation of T cells was inhibited due to steric shielding, in which EBOV GP protein expressed on infected antigen presenting cells (APCs) masks its own epitopes and MHC-I and β1 integrin expressed on the cell surface [55]. Furthermore, TCR signal transduction could be inhibited via IFN-inhibiting domains located in viral VP35 and VP24 proteins when EBOV-infected DCs were in contact with T cells [157,158].

2.4. Lymphocyte Trafficking

Accumulation of lymphocytes was often observed in infected tissue sites of patients and animals, which was believed to be due to migration from peripheral blood [65,97]. The recovering SARS patients had an average increase of 121 CD4+ T cells per microliter of peripheral blood during the first month of disease onset; it is speculated that the rapid recovery in lymphocytes blood count is more likely due to the recirculation of lymphocytes between organs and peripheral blood, rather than newly produced lymphocytes [28,69]. In addition, various kinds of leucocytes infiltrate the alveoli at various degrees after SARS-CoV-2- and IAV- infections, including lymphocytes, monocytes, neutrophils and eosinophils [65,159]. Therefore, lymphocyte sequestration in lungs is considered as a potential pathway for the depletion of blood lymphocytes [160]. Similarly, the loss of circulating lymphocytes temporally coincides with the accumulation of lymphocytes in the lymph nodes and jejunal mucosa following HIV-, SIV- and HNoV-infection, which suggests that lymphopenia may occur as a result of the redistribution of circulating lymphocytes to the infected sites [50,97,161]. Although the molecular mechanism for lymphocytes trafficking remains unclear, it seems that CXCL13, IP10 and IFN-α/β play an important role in lymphocyte trafficking [42,44,140].

2.5. Role of Co-Inhibitory Molecules

T cell activation requires two signals: TCR stimulation through antigen recognition in the context of MHC and co-stimulation through interaction of co-signaling receptors (co-stimulatory and co-inhibitory receptors) on T cells with their ligands on APCs [162]. Co-signaling receptors play a pivotal role in regulating T cell activation, subset differentiation, effector function and survival [162]. Co-inhibitory molecules include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin mucin 3 (Tim-3) and 2B4. Up-regulated expression of these co-inhibitory molecules has been reported following viral infection, such as SARS-CoV-2 [22], HIV [45], EBOV [56], IAV [66] and RSV [77]. It is noted that the expression of PD-1, LAG-3 and TIGIT in CD4+ T cells showed the strongest inverse associations with the number of CD4+ T cell from AIDS patients [45]. During high-pathological IAV infection, the expression of PD-1 on CD8+ T cells specific for IAV was upregulated, and blockade of PD-L1 in vivo caused reduced titers of virus and increased numbers of CD8+ T cell numbers [66]. PD-1 has been reported to promote T cells exhaustion and apoptosis and to inhibit proliferation, cytokines production and cytolytic function by regulating signaling of AKT, phosphoinositide 3-kinase (PI3K), extracellular-signal regulated kinase (ERK) and phosphoinositide phospholipase C-γ (PLCγ) [163]. A recent study demonstrated that PD-1-mediated PI3K/Akt/mTOR, caspase9/caspase3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection. The molecular mechanism of other co-inhibitory molecules in lymphopenia caused by viral infection needs further study.

2.6. Metabolic Disorders

Lactic acid environments in tumors have been confirmed to suppress the proliferation and cytokines production of human CTLs and lead to a 50% decrease in cytotoxic activity, and the CTLs function can be restored in a lactic acid-free medium [164]. The level of lactic acid was significantly upregulated in severe COVID-19 patients compared to mild patients [165]. It is speculated that the elevated blood lactic acid levels in severe COVID-19 patients might suppress the proliferation of lymphocytes. In addition, the bilirubin levels (the marker of liver damage), urea nitrogen and creatinine (the markers of renal function) were significantly increased in severe COVID-19 patients [5,166,167]. The damage of these organs, especially liver and kidney, may affect the survival, production and function of lymphocytes. Similarly, RSV infected patients who required ICU showed a higher level of prolactin and growth hormone, while the leptin and insulin-like growth factor 1 (IGF1) were obviously decreased [78]. Further analysis revealed that the levels of prolactin and leptin were related to lymphocyte counts, which were considered as potential factors related to lymphopenia in severe RSV infection [78]. Overall, metabolic disorders might shift the normal physiological condition into a pathophysiological situation that may affect the production, survival and function of lymphocytes.

2.7. Glucocorticoids

Glucocorticoids not only exhibit anti-inflammatory actions but also trigger lymphocytes apoptosis that further contributes to lymphopenia [168,169]. Previous studies suggested that lymphopenia was more prevalent in SARS patients with higher prevailing cortisol, before any steroid therapy had been used [170]. Similarly, the blood cortisol was significantly higher during the active phase than during the convalescent phase after RSV- and EBOV-infection [78,171]. These phenomena revealed that glucocorticoids may be involved in lymphopenia. The role of glucocorticoids in lymphopenia has been reviewed by Panesar N.S. [31]. A recent review study described that the ordering between lymphopenia and lymphocytes apoptosis appears different in SARS and COVID-19 patients (apoptosis is prior to lymphopenia in COVID-19 patients), and the level of glucocorticoids could determine the ordering between lymphopenia [32]. Therefore, glucocorticoids appear to play an important role in lymphopenia caused by virus infections, and glucocorticoids as a drug should be used carefully for treatment in patients with lymphopenia.

3. Clinical Implications of Lymphopenia during Viral Infections

3.1. Association of Lymphopenia with Viral Disease Severity

Several studies have shown that severe and critically ill individuals during viral infection (such as SARS-CoV-2 or EBOV or AIV), who required intensive care unit (ICU), had obviously lower lymphocyte counts compared to those in healthy, mild or recovered individuals [13,172,173,174]. This phenomenon indicated that the degree of lymphocyte count has been associated with disease severity [174,175,176]. T cells play a critical role in virus-specific, adaptive immune response, thereby suggesting that lymphopenia could severely impair the body’s ability to fight infection. Likewise, Xu et al. also pointed out that SARS-CoV-2 leads to lymphocyte depletion and inhibits immune function, which is a potential immunological mechanism for the occurrence and progression of COVID-19 [177]. Moreover, lymphocyte counts in blood is also a viable and accurate index to classify the severity (moderate, severe and critical) of COVID-19 patients [12]. Therefore, lymphopenia could be a clinical indicator for ranking the severity of COVID-19 patients. Similarly, following infections of FIPV [178] and RHDV [179], lymphopenia is also related to the severity of disease. A previous study indicated that lymphopenia was related to disease severity in FIPV infection, and the absolute count of lymphocytes in peripheral blood was recognized as the predictor of the disease outcome [178]. In addition, severe lymphocytes depletion was observed in rabbits infected with RHDV, especially at 6 h before death of the infected rabbits [99]. Although it is not clear whether lymphopenia promotes the progression of the disease or the severe disease contributes to lymphopenia, it determines that lymphopenia is associated with the severity of the disease. Lymphopenia also can be served as an important indicator for dynamic assessment of disease status.

3.2. Increases in Opportunistic Infection

Patients with immunosuppressive conditions are prone to have opportunistic infection, which could be either severe or more frequent. Opportunistic infection is a significant feature during the HIV infection, which could result in high morbidity and even mortality [180,181]. Lymphopenia is likely to delay viral clearance, in favor of macrophage stimulation and the accompanying “cytokine storm”, which results in the dysfunction of host organs [14,182]. These damages could increase the risk of developing opportunistic infections. A report described that lymphopenia in COVID-19 patients could increase the risk of developing opportunistic infections of mucormycosis, while the recovery of lymphocytes count could improve the acquired immune response and induce the production of mucorales-specific T cells [183]. To the best of our knowledge, there are few reports of opportunistic infections in specific viral diseases accompanied by lymphopenia. Therefore, further investigations are required to reveal the relationship between opportunistic infection and lymphopenia.

4. Conclusions

Lymphocytes, especially specific T cells, have a critical role in viral clearance. Thus, lymphopenia may affect the host adaptive immune responses and impact the clinical course of acute viral infections. In this review, we found that lymphopenia was often seen in patients and animals infected with viruses that could result in serious illness or even death and it was found that lymphopenia is associated with disease severity. Seven different mechanisms were involved in lymphopenia caused by viral infections, including cell death, elevated cytokines, chemokines and growth factors, inhibition of lymphopoiesis, lymphocyte trafficking, up-regulated expression of co-inhibitory molecules, metabolic disorders and elevated glucocorticoids. As it has been discussed in this review, lymphopenia could be caused by different viral infections through multiple mechanisms mentioned above or depending on a certain mechanism. Although the potential mechanisms have been widely reported, the molecular mechanism of these pathways still remains poorly understood, which needs to be addressed in the future.

Author Contributions

Conceptualization, Z.G. and Y.L.; writing—original draft preparation, Z.G.; writing—review and editing, Z.Z., M.P. and Y.L.; funding acquisition, Z.Z. and Y.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Southwest Minzu University Research Startup Fund (125900/16011211013) and Gansu Province Science and Technology Planning Project (20YF3WA008).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We would like to acknowledge Shuaiyang Zhao for assistance with Figure 1.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Abbreviations

T cellsT lymphocytes
B cellsB lymphocytes
NK cellsNatural killer cells
SARS-CoV-2Severe acute respiratory syndrome coronavirus-2
EBOVEbola virus
HIVHuman immunodeficiency virus
MERS-CoVMiddle east respiratory syndrome coronavirus
SARS-CoVSevere acute respiratory syndrome coronavirus
FIPVFeline infectious peritonitis virus
CCoVCanine coronavirus
ECoVEquine coronavirus
SIVSimian im-munodeficiency virus
BLVBovine leukemia virus
MARVMarburg virus
BDBVBun-dibugyo virus
IAVInfluenza A virus
MVMeasles virus
HPIV3Human parainfluenza virus type 3
CDVCanine distemper virus
PPRVPeste des petits ruminants virus
RSVRespiratory syncytial virus
PRRSVPorcine reproductive and respiratory syndrome virus
FMDVFoot-and-mouth disease virus
SVVSeneca Valley virus
CSFVClassical swine fever virus
HCVHepatitis C virus
BDVBorder disease virus
DENVDengue Virus
WNVWest Nile virus
BVDVBovine viral diarrhoea virus
HNoVHuman no-rovirus
RHDVRabbit haemorrhagic disease virus
FCVFeline calicivirus
LCMVLymphocytic choriomeningitis virus
CHIKVChikungunya virus
ASFVAfrican swine fever virus
PCV-2Porcine circovirus type 2
CMVCytomegalovirus
MDVMarek’s disease virus
HSVHerpes simplex virus
FPVFeline parvovirus
CPVCanine parvovirus
CTLCytotoxic T lymphocyte
ADCCAntibody-dependent cell-mediated cytotoxicity
AICDActivation-induced cell death
TCRT cell receptor
DCDendritic cell
pDCsPlasmacytoid dendritic cells
TUNELTdT-mediated dUTP nick-end labeling
TRAILTNF-related apoptosis-inducing ligand
CD95LCD95 ligand
IFNsInterferons
HPCHaematopoietic precursor cells
APCsAntigen presenting cells
CTLA-4Cytotoxic T-lymphocyte-associated protein 4
PD-1Programmed death 1
TIGITT cell immunoreceptor with Ig and ITIM domains
LAG-3Lym-phocyte activation gene-3
Tim-3T cell immunoglobulin mucin 3
PI3Kphosphoinositide 3-kinase
ERKExtracellular-signal regulated kinase
PLCγPhosphoinositide phospholipase C-γ
IGF1Insulin-like growth factor 1
ICUIntensive care unit.

References

  1. Ratajczak, W.; Niedźwiedzka-Rystwej, P.; Tokarz-Deptuła, B.; Deptuła, W. Immunological memory cells. Cent. Eur. J. Immunol. 2018, 43, 194–203. [Google Scholar] [CrossRef]
  2. Kim, Y.R.; Kim, S.J.; Jung, H.A.; Kim, S.J.; Kim, W.S.; Lee, H.W.; Eom, H.S.; Jeong, S.H.; Park, J.S.; Cheong, J.-W.; et al. Lymphopenia is an important prognostic factor in peripheral T cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J. Hematol. Oncol. 2011, 4, 34. [Google Scholar] [CrossRef] [Green Version]
  3. Mitrovic, Z.; Suzumiya, J.; Armitage, J.O.; Au, W.Y.; Coiffier, B.; Holte, H.; Jaffe, E.S.; Monserrat, E.; Rajan, S.K.; Savage, K.J.; et al. The prognostic significance of lymphopenia in peripheral T cell and natural killer/T cell lymphomas: A study of 826 cases from the International Peripheral T cell Lymphoma Project. Am. J. Hematol. 2012, 87, 790–794. [Google Scholar] [CrossRef]
  4. Ray-Coquard, I.; Van Glabbeke, M.; Sebban, C.; Le Cesne, A.; Judson, I.; Tredan, O.; Verweij, J.; Biron, P.; Labidi, I.; Guastalla, J.-P.; et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009, 69, 5383–5391. [Google Scholar] [CrossRef] [Green Version]
  5. Zhang, J.; Cao, Y.; Tan, G.; Dong, X.; Wang, B.; Lin, J.; Yan, Y.; Liu, G.; Akdis, M.; Akdis, C.A.; et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2020, 76, 533–550. [Google Scholar] [CrossRef]
  6. Lin, A.J.; Rao, Y.J.; Chin, R.-I.; Campian, J.; Mullen, D.; Thotala, D.; Daly, M.; Gay, H.; Oppelt, P.; Hallahan, D.; et al. Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. Oral Oncol. 2018, 86, 1–7. [Google Scholar] [CrossRef]
  7. Merayo-Chalico, J.; Rajme-López, S.; Barrera-Vargas, A.; Alcocer-Varela, J.; Díaz-Zamudio, M.; Gómez-Martín, D. Lymphopenia and autoimmunity: A double-edged sword. Hum. Immunol. 2016, 77, 921–929. [Google Scholar] [CrossRef]
  8. Puck, J.M. Newborn screening for severe combined immunodeficiency and T cell lymphopenia. Immunol. Rev. 2018, 287, 241–252. [Google Scholar] [CrossRef]
  9. Ménétrier-Caux, C.; Ray-Coquard, I.; Blay, J.-Y.; Caux, C. Lymphopenia in cancer patients and its effects on response to immunotherapy: An opportunity for combination with Cytokines? J. Immunother. Cancer 2019, 7, 85. [Google Scholar] [CrossRef] [Green Version]
  10. Drewry, A.M.; Samra, N.; Skrupky, L.P.; Fuller, B.; Compton, S.M.; Hotchkiss, R.S. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 2014, 42, 383–391. [Google Scholar] [CrossRef] [Green Version]
  11. Girardot, T.; Rimmelé, T.; Venet, F.; Monneret, G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis 2016, 22, 295–305. [Google Scholar] [CrossRef]
  12. Henry, B.; Cheruiyot, I.; Vikse, J.; Mutua, V.; Kipkorir, V.; Benoit, J.; Plebani, M.; Bragazzi, N.; Lippi, G. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: A meta-analysis. Acta Bio Med. Atenei Parm. 2020, 91, e2020008. [Google Scholar] [CrossRef]
  13. Younan, P.; Santos, R.I.; Ramanathan, P.; Iampietro, M.; Nishida, A.; Dutta, M.; Ammosova, T.; Meyer, M.; Katze, M.G.; Popov, V.L.; et al. Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection. PLoS Pathog. 2019, 15, e1008068. [Google Scholar] [CrossRef]
  14. Peng, X.; Ouyang, J.; Isnard, S.; Lin, J.; Fombuena, B.; Zhu, B.; Routy, J.-P. Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. Front. Immunol. 2020, 11, 596631. [Google Scholar] [CrossRef] [PubMed]
  15. Xiong, Y.; Liu, Y.; Cao, L.; Wang, D.; Guo, M.; Jiang, A.; Guo, D.; Hu, W.; Yang, J.; Tang, Z.; et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes. Infect. 2020, 9, 761–770. [Google Scholar] [CrossRef] [PubMed]
  16. Xiao, A.T.; Gao, C.; Zhang, S. Profile of specific antibodies to SARS-CoV-2: The first report. J. Infect. 2020, 81, 147–178. [Google Scholar] [CrossRef]
  17. Xu, Z.-S.; Shu, T.; Kang, L.; Wu, D.; Zhou, X.; Liao, B.-W.; Sun, X.-L.; Zhou, X.; Wang, Y.-Y. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal. Transduct. Target. Ther. 2020, 5, 1–3. [Google Scholar] [CrossRef] [PubMed]
  18. Diao, B.; Wang, C.; Tan, Y.; Chen, X.; Liu, Y.; Ning, L.; Chen, L.; Li, M.; Liu, Y.; Wang, G.; et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 2020, 11, 827. [Google Scholar] [CrossRef]
  19. Quartuccio, L.; Fabris, M.; Sonaglia, A.; Peghin, M.; Domenis, R.; Cifù, A.; Curcio, F.; Tascini, C. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. Cytokine 2021, 140, 155438. [Google Scholar] [CrossRef]
  20. Ratajczak, M.Z.; Kucia, M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leukemia 2020, 34, 1726–1729. [Google Scholar] [CrossRef]
  21. Zhou, R.; To, K.K.; Wong, Y.C.; Liu, L.; Zhou, B.; Li, X.; Huang, H.; Mo, Y.; Luk, T.Y.; Lau, T.T.; et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 2020, 53, 864–877. [Google Scholar] [CrossRef]
  22. Bellesi, S.; Metafuni, E.; Hohaus, S.; Maiolo, E.; Marchionni, F.; D’Innocenzo, S.; La Sorda, M.; Ferraironi, M.; Ramundo, F.; Fantoni, M.; et al. Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. Br. J. Haematol. 2020, 191, 207–211. [Google Scholar] [CrossRef]
  23. Liang, Y.; Wang, M.-L.; Chien, C.-S.; Yarmishyn, A.A.; Yang, Y.-P.; Lai, W.-Y.; Luo, Y.-H.; Lin, Y.-T.; Chen, Y.-J.; Chang, P.-C.; et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-CoV-2 infection. Front. Immunol. 2020, 11, 1022. [Google Scholar] [CrossRef]
  24. Chu, H.; Zhou, J.; Wong, B.H.-Y.; Li, C.; Chan, J.F.-W.; Cheng, Z.-S.; Yang, D.; Wang, D.; Lee, A.C.Y.; Li, C.; et al. Middle east respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J. Infect. Dis. 2015, 213, 904–914. [Google Scholar] [CrossRef] [Green Version]
  25. Assiri, A.; Al-Tawfiq, J.A.; Al-Rabeeah, A.A.; Al-Rabiah, F.A.; Al-Hajjar, S.; Al-Barrak, A.; Flemban, H.; Al-Nassir, W.N.; Balkhy, H.H.; Al-Hakeem, R.F.; et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect. Dis. 2013, 13, 752–761. [Google Scholar] [CrossRef] [Green Version]
  26. Leung, C.; Gomersall, C.D. Middle East respiratory syndrome. Intensive Care Med. 2014, 40, 1015–1017. [Google Scholar] [CrossRef] [Green Version]
  27. Wong, C.K.; Lam, C.W.K.; Wu, A.K.L.; Ip, W.K.; Lee, N.; Chan, I.H.S.; Lit, L.C.W.; Hui, D.; Chan, M.H.M.; Chung, S.S.C.; et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004, 136, 95–103. [Google Scholar] [CrossRef] [Green Version]
  28. Li, T.; Qiu, Z.; Zhang, L.; Han, Y.; He, W.; Liu, Z.; Ma, X.; Fan, H.; Lu, W.; Xie, J.; et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 2004, 189, 648–651. [Google Scholar] [CrossRef] [Green Version]
  29. Wong, R.; Wu, A.; To, K.F.; Lee, N.; Lam, C.W.K.; Wong, C.K.; Chan, P.; Ng, M.H.L.; Yu, L.M.; Hui, D.; et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ 2003, 326, 1358–1362. [Google Scholar] [CrossRef] [Green Version]
  30. He, Z.; Zhao, C.; Dong, Q.; Zhuang, H.; Song, S.; Peng, G.; Dwyer, D.E. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int. J. Infect. Dis. 2005, 9, 323–330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Panesar, N. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med. Hypotheses 2008, 71, 298–301. [Google Scholar] [CrossRef]
  32. Yan, S.; Wu, G. Is lymphopenia different between SARS and COVID-19 patients? FASEB J. 2021, 35, e21245. [Google Scholar] [CrossRef]
  33. Takano, T.; Hohdatsu, T.; Hashida, Y.; Kaneko, Y.; Tanabe, M.; Koyama, H. A “possible” involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Veter. Microbiol. 2007, 119, 121–131. [Google Scholar] [CrossRef] [PubMed]
  34. Haagmans, B.L.; Egberink, H.; Horzinek, M.C. Apoptosis and T cell depletion during feline infectious peritonitis. J. Virol. 1996, 70, 8977–8983. [Google Scholar] [CrossRef] [Green Version]
  35. Dean, G.A.; Olivry, T.; Stanton, C.; Pedersen, N.C. In vivo cytokine response to experimental feline infectious peritonitis virus infection. Veter. Microbiol. 2003, 97, 1–12. [Google Scholar] [CrossRef]
  36. Vermeulen, B.L.; Devriendt, B.; Olyslaegers, D.A.; Dedeurwaerder, A.; Desmarets, L.M.; Favoreel, H.; Dewerchin, H.L.; Nauwynck, H.J. Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Veter. Microbiol. 2013, 164, 46–59. [Google Scholar] [CrossRef]
  37. Decaro, N.; Elia, G.; Martella, V.; Campolo, M.; Mari, V.; Desario, C.; Lucente, M.S.; Lorusso, E.; Kanellos, T.; Gibbons, R.H.; et al. Immunity after natural exposure to enteric canine coronavirus does not provide complete protection against infection with the new pantropic CB/05 strain. Vaccine 2010, 28, 724–729. [Google Scholar] [CrossRef]
  38. Pusterla, N.; Vin, R.; Leutenegger, C.; Mittel, L.; Divers, T. Enteric coronavirus infection in adult horses. Veter. J. 2017, 231, 13–18. [Google Scholar] [CrossRef]
  39. Garg, H.; Mohl, J.; Joshi, A. HIV-1 Induced Bystander Apoptosis. Viruses 2012, 4, 3020–3043. [Google Scholar] [CrossRef]
  40. Doitsh, G.; Galloway, N.L.K.; Geng, X.; Yang, Z.; Monroe, K.M.; Zepeda, O.; Hunt, P.W.; Hatano, H.; Sowinski, S.; Muñoz-Arias, I.; et al. Cell death by pyroptosis drives CD4 T cell depletion in HIV-1 infection. Nature 2013, 505, 509–514. [Google Scholar] [CrossRef] [Green Version]
  41. Denizot, M.; Varbanov, M.; Espert, L.; Robert-Hebmann, V.; Sagnier, S.; Garcia, E.G.E.; Curriu, M.; Mamoun, R.; Blanco, J.; Biard-Piechaczyk, M. HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy 2008, 4, 998–1008. [Google Scholar] [CrossRef] [Green Version]
  42. Muema, D.; Akilimali, N.A.; Ndumnego, O.; Rasehlo, S.S.; Durgiah, R.; Ojwach, D.B.; Ismail, N.; Dong, M.; Moodley, A.; Dong, K.L.; et al. Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. BMC Med. 2020, 18, 1–17. [Google Scholar] [CrossRef] [Green Version]
  43. Palmer, B.E.; Blyveis, N.; Fontenot, A.P.; Wilson, C.C. Functional and phenotypic characterization of CD57+CD4+T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 2005, 175, 8415–8423. [Google Scholar] [CrossRef] [Green Version]
  44. Wang, L.; Robb, C.W.; Cloyd, M.W. HIV induces homing of resting T lymphocytes to lymph nodes. Virology 1997, 228, 141–152. [Google Scholar] [CrossRef]
  45. Fromentin, R.; Bakeman, W.; Lawani, M.B.; Khoury, G.; Hartogensis, W.; DaFonseca, S.; Killian, M.; Epling, L.; Hoh, R.; Sinclair, E.; et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV persistence during ART. PLoS Pathog. 2016, 12, e1005761. [Google Scholar] [CrossRef]
  46. Bhardwaj, S.; Almaeen, A.; Wani, F.A.; Thirunavukkarasu, A. Hematologic derangements in HIV/AIDS patients and their relationship with the CD4 counts: A cross-sectional study. Int. J. Clin. Exp. Pathol. 2020, 13, 756–763. [Google Scholar]
  47. Parinitha, S.; Kulkarni, M. Haematological changes in HIV infection with correlation to CD4 cell count. Australas. Med. J. 2012, 5, 157–162. [Google Scholar] [CrossRef]
  48. Meythaler, M.; Martinot, A.; Wang, Z.; Pryputniewicz, S.; Kasheta, M.; Ling, B.; Marx, P.A.; O’Neil, S.; Kaur, A. Differential CD4 + T-Lymphocyte apoptosis and bystander T Cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection. J. Virol. 2009, 83, 572–583. [Google Scholar] [CrossRef] [Green Version]
  49. Iida, T.; Ichimura, H.; Shimada, T.; Ibuki, K.; Ui, M.; Tamaru, K.; Kuwata, T.; Yonehara, S.; Imanishi, J.; Hayami, M. Role of apoptosis induction in both peripheral lymph nodes and thymus in progressive loss of CD4+ cells in shiv-infected macaques. AIDS Res. Hum. Retrovir. 2000, 16, 9–18. [Google Scholar] [CrossRef]
  50. Ponte, R.; Rancez, M.; Figueiredo-Morgado, S.; Dutrieux, J.; Fabre-Mersseman, V.; Charmeteau-De-Muylder, B.; Guilbert, T.; Routy, J.-P.; Cheynier, R.; Couedel-Courteille, A. Acute simian immunodeficiency virus infection triggers early and transient Interleukin-7 production in the gut, leading to enhanced local chemokine expression and intestinal immune cell homing. Front. Immunol. 2017, 8, 588. [Google Scholar] [CrossRef]
  51. Beyer, J.; Kollner, B.; Teifke, J.P.; Starick, E.; Beier, D.; Reimann, I.; Grunwald, U.; Ziller, M. Cattle infected with bovine leukaemia virus may not only develop persistent B cell lymphocytosis but also persistent B cell lymphopenia. J. Veter. Med. Ser. B 2002, 49, 270–277. [Google Scholar] [CrossRef]
  52. Messaoudi, I.; Amarasinghe, G.K.; Basler, C.F. Filovirus pathogenesis and immune evasion: Insights from Ebola virus and Marburg virus. Nat. Rev. Genet. 2015, 13, 663–676. [Google Scholar] [CrossRef] [Green Version]
  53. McElroy, A.; Erickson, B.R.; Flietstra, T.D.; Rollin, P.; Nichol, S.T.; Towner, J.S.; Spiropoulou, C.F. Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome. J. Infect. Dis. 2014, 210, 558–566. [Google Scholar] [CrossRef] [Green Version]
  54. Bosio, C.M.; Grogan, C.; Hogan, R.; Ruthel, G.; Negley, D.; Mohamadzadeh, M.; Bavari, S.; Schmaljohn, A.; Schmaljohn, A. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 2003, 188, 1630–1638. [Google Scholar] [CrossRef] [Green Version]
  55. Reynard, O.; Borowiak, M.; Volchkova, V.A.; Delpeut, S.; Mateo, M.; Volchkov, V.E. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J. Virol. 2009, 83, 9596–9601. [Google Scholar] [CrossRef] [Green Version]
  56. Ruibal, P.; Oestereich, L.; Lüdtke, A.; Becker-Ziaja, B.; Wozniak, D.; Kerber, R.; Korva, M.; Cabeza-Cabrerizo, M.; Bore, J.A.; Koundouno, F.R.; et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 2016, 533, 100–104. [Google Scholar] [CrossRef]
  57. Ewers, E.C.; Pratt, W.D.; Twenhafel, N.A.; Shamblin, J.; Donnelly, G.; Esham, H.; Wlazlowski, C.; Johnson, J.C.; Botto, M.; Hensley, L.E.; et al. Natural history of aerosol exposure with marburg virus in rhesus macaques. Viruses 2016, 8, 87. [Google Scholar] [CrossRef] [Green Version]
  58. Fernando, L.; Qiu, X.; Melito, P.L.; Williams, K.J.N.; Feldmann, F.; Feldmann, H.; Jones, S.M.; Alimonti, J.B. Immune response to marburg virus angola infection in nonhuman primates. J. Infect. Dis. 2015, 212, S234–S241. [Google Scholar] [CrossRef] [Green Version]
  59. Geisbert, T.W.; Hensley, L.; Gibb, T.R.; Steele, K.E.; Jaax, N.K.; Jahrling, P.B. Apoptosis induced in vitro and in vivo during infection by ebola and marburg viruses. Lab. Investig. 2000, 80, 171–186. [Google Scholar] [CrossRef] [Green Version]
  60. Kozak, R.; He, S.; Kroeker, A.; de La Vega, M.-A.; Audet, J.; Wong, G.; Urfano, C.; Antonation, K.; Embury-Hyatt, C.; Kobinger, G.P.; et al. Ferrets infected with bundibugyo virus or ebola virus recapitulate important aspects of human filovirus disease. J. Virol. 2016, 90, 9209–9223. [Google Scholar] [CrossRef] [Green Version]
  61. Boonnak, K.; Vogel, L.; Feldmann, F.; Feldmann, H.; Legge, K.L.; Subbarao, K. Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic Cell–mediated apoptosis of T cells. J. Immunol. 2014, 192, 5906–5912. [Google Scholar] [CrossRef]
  62. Nichols, J.E.; Niles, J.A.; Roberts, N.J. Human lymphocyte apoptosis after exposure to influenza a virus. J. Virol. 2001, 75, 5921–5929. [Google Scholar] [CrossRef] [Green Version]
  63. Gu, Y.; Hsu, A.C.-Y.; Pang, Z.; Pan, H.; Zuo, X.; Wang, G.; Zheng, J.; Wang, F. Role of the innate cytokine storm induced by the influenza a virus. Viral Immunol. 2019, 32, 244–251. [Google Scholar] [CrossRef]
  64. Smed-Sörensen, A.; Chalouni, C.; Chatterjee, B.; Cohn, L.; Blattmann, P.; Nakamura, N.; Delamarre, L.; Mellman, I. Influenza a virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells. PLoS Pathog. 2012, 8, e1002572. [Google Scholar] [CrossRef] [Green Version]
  65. Denney, L.; Aitken, C.; Li, C.K.-F.; Wilson-Davies, E.; Kok, W.L.; Clelland, C.; Rooney, K.; Young, J.D.; Dong, T.; McMichael, A.J.; et al. Reduction of natural killer but Not Effector CD8 T lymphoyctes in three consecutive cases of severe/Lethal H1N1/09 influenza a virus infection. PLoS ONE 2010, 5, e10675. [Google Scholar] [CrossRef]
  66. Rutigliano, J.A.; Sharma, S.; Morris, M.Y.; Oguin, T.H.; McClaren, J.L.; Doherty, P.C.; Thomas, P.G. Highly pathological influenza a virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T Cells. J. Virol. 2013, 88, 1636–1651. [Google Scholar] [CrossRef] [Green Version]
  67. De Swart, R.L.; Ludlow, M.; De Witte, L.; Yanagi, Y.; Van Amerongen, G.; McQuaid, S.; Yüksel, S.; Geijtenbeek, T.B.H.; Duprex, W.P.; Osterhaus, A. Predominant Infection of CD150+ Lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog. 2007, 3, e178. [Google Scholar] [CrossRef] [PubMed]
  68. Laksono, B.M.; De Vries, R.D.; McQuaid, S.; Duprex, W.P.; De Swart, R.L. Measles virus host invasion and pathogenesis. Viruses 2016, 8, 210. [Google Scholar] [CrossRef] [Green Version]
  69. Gul, A.; Khan, S.; Arshad, M.; Anjum, S.I.; Attaullah, S.; Ali, I.; Rauf, A.; Arshad, A.; Alghanem, S.M.; Khan, S.N. Peripheral blood T cells response in human parainfluenza virus-associated lower respiratory tract infection in children. Saudi J. Biol. Sci. 2020, 27, 2847–2852. [Google Scholar] [CrossRef]
  70. Schobesberger, M.; Summerfield, A.; Doherr, M.; Zurbriggen, A.; Griot, C. Canine distemper virus-induced depletion of uninfected lymphocytes is associated with apoptosis. Veter. Immunol. Immunopathol. 2005, 104, 33–44. [Google Scholar] [CrossRef]
  71. Kajita, M.; Katayama, H.; Murata, T.; Kai, C.; Hori, M.; Ozaki, H. Canine distemper virus induces apoptosis through Caspase-3 and -8 activation in vero cells. J. Veter. Med. Ser. B 2006, 53, 273–277. [Google Scholar] [CrossRef]
  72. Beineke, A.; Puff, C.; Seehusen, F.; Baumgärtner, W. Pathogenesis and immunopathology of systemic and nervous canine distemper. Veter. Immunol. Immunopathol. 2009, 127, 1–18. [Google Scholar] [CrossRef]
  73. Kumar, N.; Maherchandani, S.; Kashyap, S.K.; Singh, S.V.; Sharma, S.; Chaubey, K.K.; Ly, H. Peste Des petits ruminants virus infection of small ruminants: A comprehensive review. Viruses 2014, 6, 2287–2327. [Google Scholar] [CrossRef] [Green Version]
  74. Sharma, C.S.; Mehta, H.K.; Prakash, M.M.; Shukla, P.C. Studies on clinico-haemato-biochemical changes in peste des petits ruminants in goats. Veterinary Practitioner. 2012, 13, 322–325. [Google Scholar]
  75. Russell, C.D.; Unger, S.A.; Walton, M.; Schwarze, J. The human immune response to respiratory syncytial virus infection. Clin. Microbiol. Rev. 2017, 30, 481–502. [Google Scholar] [CrossRef] [Green Version]
  76. Roe, M.F.E.; Bloxham, D.M.; White, D.K.; Ross-Russell, R.I.; Tasker, R.; O’Donnell, D.R. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin. Exp. Immunol. 2004, 137, 139–145. [Google Scholar] [CrossRef] [Green Version]
  77. Yao, S.; Jiang, L.; Moser, E.; Jewett, L.B.; Wright, J.R.; Du, J.; Zhou, B.; Davis, S.D.; Krupp, N.L.; Braciale, T.J.; et al. Control of pathogenic effector T cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. Mucosal Immunol. 2014, 8, 746–759. [Google Scholar] [CrossRef] [Green Version]
  78. Tasker, R.C.; Roe, M.F.E.; Bloxham, D.M.; White, D.K.; Ross-Russell, R.I.; O’Donnell, D.R. The neuroendocrine stress response and severity of acute respiratory syncytial virus bronchiolitis in infancy. Intensiv. Care Med. 2004, 30, 2257–2262. [Google Scholar] [CrossRef]
  79. Han, J.; Zhou, L.; Ge, X.; Guo, X.; Yang, H. Pathogenesis and control of the Chinese highly pathogenic porcine reproductive and respiratory syndrome virus. Veter. Microbiol. 2017, 209, 30–47. [Google Scholar] [CrossRef]
  80. Canelli, E.; Catella, A.; Borghetti, P.; Ferrari, L.; Ogno, G.; De Angelis, E.; Corradi, A.; Passeri, B.; Bertani, V.; Sandri, G.; et al. Phenotypic characterization of a highly pathogenic Italian porcine reproductive and respiratory syndrome virus (PRRSV) type 1 subtype 1 isolate in experimentally infected pigs. Veter. Microbiol. 2017, 210, 124–133. [Google Scholar] [CrossRef]
  81. Bautista, E.M.; Ferman, G.S.; Golde, W.T. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV). Veter. Immunol. Immunopathol. 2003, 92, 61–73. [Google Scholar] [CrossRef]
  82. Segundo, F.D.-S.; Salguero, F.J.; de Avila, A.; de Marco, M.M.F.; Sánchez-Martín, M.A.; Sevilla, N. Selective lymphocyte depletion during the early stage of the immune response to foot-and-mouth disease virus infection in swine. J. Virol. 2006, 80, 2369–2379. [Google Scholar] [CrossRef] [Green Version]
  83. Joshi, G.; Sharma, R.; Kakker, N.K. Phenotypic and functional characterization of T cells and in vitro replication of FMDV serotypes in bovine lymphocytes. Vaccine 2009, 27, 6656–6661. [Google Scholar] [CrossRef]
  84. Nfon, C.K.; Toka, F.N.; Kenney, M.; Pacheco, J.; Golde, W.T. Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection. Viral Immunol. 2010, 23, 29–41. [Google Scholar] [CrossRef]
  85. Eschbaumer, M.; Stenfeldt, C.; Rekant, S.I.; Pacheco, J.M.; Hartwig, E.J.; Smoliga, G.R.; Kenney, M.A.; Golde, W.T.; Rodriguez, L.L.; Arzt, J. Systemic immune response and virus persistence after foot-and-mouth disease virus infection of naïve cattle and cattle vaccinated with a homologous adenovirus-vectored vaccine. BMC Veter. Res. 2016, 12, 205. [Google Scholar] [CrossRef] [Green Version]
  86. De Oliveira, T.E.S.; Leme, R.A.; Agnol, A.M.D.; Gerez, J.R.; Pelaquim, I.F.; Miyabe, F.M.; Alfieri, A.F.; Alfieri, A.A.; Headley, S.A. Seneca valley virus induces immunodepressionin suckling piglets by selective apoptosis of B lymphocytes. Microb. Pathog. 2021, 158, 105022. [Google Scholar] [CrossRef]
  87. Yuan, J.; Zhu, M.; Deng, S.; Fan, S.; Xu, H.; Liao, J.; Li, P.; Zheng, J.; Zhao, M.; Chen, J. Classical swine fever virus induces pyroptosis in the peripheral lymphoid organs of infected pigs. Virus Res. 2018, 250, 37–42. [Google Scholar] [CrossRef]
  88. Summerfield, A.; Alves, M.; Ruggli, N.; De Bruin, M.; McCullough, K. High IFN-αResponses associated with depletion of lymphocytes and natural IFN-Producing cells during classical swine fever. J. Interf. Cytokine Res. 2006, 26, 248–255. [Google Scholar] [CrossRef]
  89. Ma, S.-M.; Mao, Q.; Yi, L.; Zhao, M.-Q.; Chen, J.-D. Apoptosis, autophagy, and pyroptosis: Immune escape strategies for persistent infection and pathogenesis of classical swine fever virus. Pathogens 2019, 8, 239. [Google Scholar] [CrossRef] [Green Version]
  90. Summerfield, A.; Zingle, K.; Inumaru, S.; McCullough, K.C. Induction of apoptosis in bone marrow neutrophil-lineage cells by classical swine fever virus. J. Gen. Virol. 2001, 82, 1309–1318. [Google Scholar] [CrossRef] [Green Version]
  91. Mahale, P.; Kontoyiannis, D.P.; Chemaly, R.F.; Jiang, Y.; Hwang, J.; Davila, M.; Torres, H.A. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J. Hepatol. 2012, 57, 1177–1185. [Google Scholar] [CrossRef]
  92. Aung, A.K.; Robinson, J.; Hey, P.; Lehmann, M.; Chow, Y.; Stark, R.J.; Bosco, J.J. Progressive multifocal leukoencephalopathy secondary to hepatitis C virus infection-related T cell lymphopenia. Intern. Med. J. 2019, 49, 114–118. [Google Scholar] [CrossRef] [Green Version]
  93. Fernández-Sirera, L.; Mentaberre, G.; López-Olvera, J.; Cuenca, R.; Lavín, S.; Marco, I. Haematology and serum chemistry of Pyrenean chamois (Rupicapra pyrenaica) naturally infected with a border disease virus. Res. Veter. Sci. 2011, 90, 463–467. [Google Scholar] [CrossRef]
  94. Le Gonidec, E.; Maquart, M.; Duron, S.; Savini, H.; Cazajous, G.; Vidal, P.-O.; Chenilleau, M.-C.; Roseau, J.-B.; Benois, A.; Déhan, C.; et al. Clinical survey of dengue virus circulation in the Republic of Djibouti between 2011 and 2014 identifies serotype 3 epidemic and recommends clinical diagnosis guidelines for resource limited settings. PLoS Negl. Trop. Dis. 2016, 10, e0004755. [Google Scholar] [CrossRef] [Green Version]
  95. Huhn, G.D.; Sejvar, J.J.; Montgomery, S.P.; Dworkin, M.S. West nile virus in the United States: An update on an emerging infectious disease. Am. Fam. Physician 2003, 68, 653–660. [Google Scholar]
  96. Liu, Y.; Liu, S.; He, B.; Wang, T.; Zhao, S.; Wu, C.; Yue, S.; Zhang, S.; He, M.; Wang, L.; et al. PD-1 blockade inhibits lymphocyte apoptosis and restores proliferation and anti-viral immune functions of lymphocyte after CP and NCP BVDV infection in vitro. Veter. Microbiol. 2018, 226, 74–80. [Google Scholar] [CrossRef]
  97. Dolin, R.; Reichman, R.C.; Fauci, A.S. Lymphocyte populations in acute viral gastroenteritis. Infect. Immun. 1976, 14, 422–428. [Google Scholar] [CrossRef] [Green Version]
  98. Alexander, W.J.; Holmes, J.R.; Shaw, J.F.E.; Riley, W.E.; Roper, W.L. Norwalk virus outbreak at a college campus. South. Med. J. 1986, 79, 33–36. [Google Scholar] [CrossRef]
  99. Ferreira, P.; Costa-E-Silva, A.; Oliveira, M.J.; Monteiro, E.; Cunha, E.; Águas, A.P. Severe leukopenia and liver biochemistry changes in adult rabbits after calicivirus infection. Res. Veter. Sci. 2006, 80, 218–225. [Google Scholar] [CrossRef]
  100. Reubel, G.H.; George, J.W.; Higgins, J.; Pedersen, N.C. Effect of chronic feline immunodeficiency virus infection on experimental feline calicivirus-induced disease. Veter Microbiol. 1994, 39, 335–351. [Google Scholar] [CrossRef]
  101. Terwee, J.; Lauritzen, A.Y.; Sabara, M.; Dreier, K.J.; Kokjohn, K. Comparison of the primary signs induced by experimental exposure to either a pneumotrophic or a ‘limping’ strain of feline calicivirus. Veter Microbiol. 1997, 56, 33–45. [Google Scholar] [CrossRef]
  102. Rodas, J.D.; Cairo, C.; Djavani, M.; Zapata, J.; Ruckwardt, T.; Bryant, J.; Pauza, C.D.; Lukashevich, I.S.; Salvato, M.S. Circulating natural killer and γδ T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Memórias Do Inst. Oswaldo Cruz 2009, 104, 583–591. [Google Scholar] [CrossRef] [Green Version]
  103. Roques, P.; Thiberville, S.-D.; Dupuis-Maguiraga, L.; Lum, F.-M.; Labadie, K.; Martinon, F.; Gras, G.; Lebon, P.; Ng, L.F.P.; De Lamballerie, X.; et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018, 10, 268. [Google Scholar] [CrossRef] [Green Version]
  104. Salguero, F.J. Comparative pathology and pathogenesis of African Swine fever infection in Swine. Front. Veter. Sci. 2020, 7, 282. [Google Scholar] [CrossRef]
  105. Nielsen, J.; Vincent, I.; Bøtner, A.; Ladekjær-Mikkelsen, A.-S.; Allan, G.; Summerfield, A.; McCullough, K. Association of lymphopenia with porcine circovirus type 2 induced postweaning multisystemic wasting syndrome (PMWS). Veter. Immunol. Immunopathol. 2003, 92, 97–111. [Google Scholar] [CrossRef]
  106. Qin, L.; Qiu, Z.; Hsieh, E.; Geng, T.; Zhao, J.; Zeng, X.; Wan, L.; Xie, J.; Ramendra, R.; Routy, J.P.; et al. Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus. Medicine 2019, 98, e16997. [Google Scholar] [CrossRef]
  107. Berthault, C.; Larcher, T.; Härtle, S.; Vautherot, J.-F.; Trapp-Fragnet, L.; Denesvre, C. Atrophy of primary lymphoid organs induced by Marek’s disease virus during early infection is associated with increased apoptosis, inhibition of cell proliferation and a severe B-lymphopenia. Veter. Res. 2018, 49, 1–18. [Google Scholar] [CrossRef] [Green Version]
  108. Perini, P.; Rinaldi, F.; Puthenparampil, M.; Marcon, M.; Perini, F.; Gallo, P. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. Mult. Scler. Relat. Disord. 2018, 26, 68–70. [Google Scholar] [CrossRef]
  109. Stuetzer, B.; Hartmann, K. Feline parvovirus infection and associated diseases. Veter. J. 2014, 201, 150–155. [Google Scholar] [CrossRef]
  110. Carman, P.; Povey, R. Pathogenesis of canine parvovirus-2 in dogs: Haematology, serology and virus recovery. Res. Veter. Sci. 1985, 38, 134–140. [Google Scholar] [CrossRef]
  111. Cotton, M.F.; Cassella, C.; Rapaport, E.L.; Tseng, P.O.; Marschner, S.; Finkel, T.H. Apoptosis in HIV-1 infection. Behring Inst. Mitt. 1996, 97, 220–231. [Google Scholar]
  112. Tsao, L.-C.; Guo, H.; Jeffrey, J.; Hoxie, J.A.; Su, L. CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo. Retrovirology 2016, 13, 22. [Google Scholar] [CrossRef] [Green Version]
  113. Rohwedder, A.; Keminer, O.; Forster, J.; Schneider, K.; Schneider, E.; Werchau, H. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. J. Med. Virol. 1998, 54, 320–327. [Google Scholar] [CrossRef]
  114. Garg, H.; Joshi, A. Host and viral factors in HIV-Mediated bystander apoptosis. Viruses 2017, 9, 237. [Google Scholar] [CrossRef] [Green Version]
  115. Brenner, D.; Blaser, H.; Mak, T.W. Regulation of tumour necrosis factor signalling: Live or let die. Nat. Rev. Immunol. 2015, 15, 362–374. [Google Scholar] [CrossRef]
  116. Del Moral, M.G.; Ortuño, E.; Fernández-Zapatero, P.; Alonso, F.; Alonso, C.; Ezquerra, A.; Domínguez, J. African Swine fever virus infection induces tumor necrosis factor alpha production: Implications in pathogenesis. J. Virol. 1999, 73, 2173–2180. [Google Scholar] [CrossRef] [Green Version]
  117. Sikora, E. Activation-induced and damage-induced cell death in aging human T cells. Mech. Ageing Dev. 2015, 151, 85–92. [Google Scholar] [CrossRef]
  118. Green, D.R.; Droin, N.; Pinkoski, M. Activation-induced cell death in T cells. Immunol. Rev. 2003, 193, 70–81. [Google Scholar] [CrossRef]
  119. Zhu, L.; Yang, P.; Zhao, Y.; Zhuang, Z.; Wang, Z.; Song, R.; Zhang, J.; Liu, C.; Gao, Q.; Xu, Q.; et al. Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity 2020, 53, 685–696. [Google Scholar] [CrossRef]
  120. Legge, K.L.; Braciale, T.J. Lymph node dendritic cells control CD8+ T cell responses through regulated fasl expression. Immunity 2005, 23, 649–659. [Google Scholar] [CrossRef] [Green Version]
  121. Langlois, R.A.; Legge, K.L. Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. J. Immunol. 2010, 184, 4440–4446. [Google Scholar] [CrossRef] [Green Version]
  122. Majumder, B.; Venkatachari, N.J.; Schafer, E.A.; Janket, M.L.; Ayyavoo, V. Dendritic cells infected with vpr -positive human immunodeficiency virus type 1 induce CD8 + T cell apoptosis via upregulation of tumor necrosis factor Alpha. J. Virol. 2007, 81, 7388–7399. [Google Scholar] [CrossRef] [Green Version]
  123. Frank, D.; Vince, J.E. Pyroptosis versus necroptosis: Similarities, differences, and crosstalk. Cell Death Differ. 2018, 26, 99–114. [Google Scholar] [CrossRef]
  124. D’Arcy, M.S. Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol. Int. 2019, 43, 582–592. [Google Scholar] [CrossRef]
  125. Barouch, D.H.; Letvin, N.L. CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr. Opin. Immunol. 2001, 13, 479–482. [Google Scholar] [CrossRef]
  126. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020, 12, 1–5. [Google Scholar] [CrossRef]
  127. Mayr, L.M.; Su, B.; Moog, C. Non-neutralizing antibodies directed against HIV and their functions. Front. Immunol. 2017, 8, 1590. [Google Scholar] [CrossRef]
  128. Wauquier, N.; Becquart, P.; Padilla, C.; Baize, S.; Leroy, E.M. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 2010, 4, e837. [Google Scholar] [CrossRef]
  129. Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Péré, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020, 369, 718–724. [Google Scholar] [CrossRef]
  130. Tanaka, T.; Narazaki, M.; Masuda, K.; Kishimoto, T. Regulation of IL-6 in immunity and diseases. Adv. Exp. Med. Biol. 2016, 941, 79–88. [Google Scholar] [CrossRef]
  131. Maeda, K.; Malykhin, A.; Teague-Weber, B.N.; Sun, X.-H.; Farris, A.D.; Coggeshall, K.M. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus–prone B6.Sle1.Yaa animals. Blood 2009, 113, 4534–4540. [Google Scholar] [CrossRef]
  132. Jenkins, B.J.; Greenhill, C.J.; Najdovska, M.; Lundgren-May, T.; Robb, L.; Grail, D.; Ernst, M.; Ernst, M. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 2007, 109, 2380–2388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  133. Palanques-Pastor, T.A.-O.; López-Briz, E.; Poveda Andrés, J.L. Involvement of interleukin 6 in SARS-CoV-2 infection: Siltuximab as a therapeutic option against COVID-19. Eur. J. Hosp. Pharm. 2020, 27, 297–298. [Google Scholar] [CrossRef]
  134. Giamarellos-Bourboulis, E.J.; Netea, M.G.; Rovina, N.; Akinosoglou, K.; Antoniadou, A.; Antonakos, N.; Damoraki, G.; Gkavogianni, T.; Adami, M.-E.; Katsaounou, P.; et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020, 27, 992–1000. [Google Scholar] [CrossRef] [PubMed]
  135. Smith, L.K.; Boukhaled, G.M.; Condotta, S.A.; Mazouz, S.; Guthmiller, J.J.; Vijay, R.; Butler, N.; Bruneau, J.; Shoukry, N.H.; Krawczyk, C.M.; et al. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-Glycan branching to decrease antigen sensitivity. Immunity 2018, 48, 299–312. [Google Scholar] [CrossRef]
  136. De Oca, M.M.; Kumar, R.; Rivera, F.D.L.; Amante, F.H.; Sheel, M.; Faleiro, R.J.; Bunn, P.T.; Best, S.E.; Beattie, L.; Ng, S.; et al. Blimp-1-dependent IL-10 production by Tr1 cells regulates TNF-mediated tissue pathology. PLoS Pathog. 2016, 12, e1005398. [Google Scholar] [CrossRef]
  137. Rojas, J.M.; Avia, M.; Martín, V.; Sevilla, N. IL-10: A multifunctional cytokine in viral infections. J. Immunol. Res. 2017, 2017, 1–14. [Google Scholar] [CrossRef] [Green Version]
  138. Ejrnaes, M.; Filippi, C.M.; Martinic, M.; Ling, E.M.; Togher, L.M.; Crotty, S.; Von Herrath, M.G. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 2006, 203, 2461–2472. [Google Scholar] [CrossRef] [PubMed]
  139. Biron, C.A. Role of early cytokines, including alpha and beta interferons (IFN-α\β), in innate and adaptive immune responses to viral infections. Semin. Immunol. 1998, 10, 383–390. [Google Scholar] [CrossRef]
  140. Kamphuis, E.; Junt, T.; Waibler, Z.; Forster, R.; Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108, 3253–3261. [Google Scholar] [CrossRef]
  141. Bixler, S.L.; Goff, A.J. The role of cytokines and chemokines in filovirus infection. Viruses 2015, 7, 5489–5507. [Google Scholar] [CrossRef]
  142. Steel, J.; Waldmann, T.A.; Morris, J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33, 35–41. [Google Scholar] [CrossRef] [Green Version]
  143. Deshmane, S.L.; Kremlev, S.; Amini, S.; Sawaya, B.E. Monocyte chemoattractant Protein-1 (MCP-1): An overview. J. Interf. Cytokine Res. 2009, 29, 313–326. [Google Scholar] [CrossRef]
  144. Kazanietz, M.G.; Durando, M.; Cooke, M. CXCL13 and Its Receptor CXCR5 in cancer: Inflammation, immune response, and beyond. Front. Endocrinol. 2019, 10, 471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  145. Hazenberg, M.D.; Hamann, D.; Schuitemaker, H.; Miedema, F. T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat. Immunol. 2000, 1, 285–289. [Google Scholar] [CrossRef]
  146. Von Messling, V.; Svitek, N.; Cattaneo, R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J. Virol. 2006, 80, 6084–6092. [Google Scholar] [CrossRef] [Green Version]
  147. Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.-Q.; Wang, Q.; Miao, H. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal. Transduct. Target. Ther. 2020, 5, 33. [Google Scholar] [CrossRef]
  148. Ye, P.; Kirschner, D.E.; Kourtis, A.P. The thymus during HIV disease: Role in pathogenesis and in immune recovery. Curr. HIV Res. 2004, 2, 177–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  149. Lins, M.P.; Smaniotto, S. Potential impact of SARS-CoV-2 infection on the thymus. Can. J. Microbiol. 2021, 67, 23–28. [Google Scholar] [CrossRef] [PubMed]
  150. Ohno, S.; Ono, N.; Seki, F.; Takeda, M.; Kura, S.; Tsuzuki, T.; Yanagi, Y. Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. J. Virol. 2007, 81, 1650–1659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  151. Vogel, A.; Haasbach, E.; Reiling, S.; Droebner, K.; Klingel, K.; Planz, O. Highly pathogenic influenza virus infection of the thymus interferes with T lymphocyte development. J. Immunol. 2010, 185, 4824–4834. [Google Scholar] [CrossRef] [PubMed]
  152. Ueda, Y.; Kondo, M.; Kelsoe, G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J. Exp. Med. 2005, 201, 1771–1780. [Google Scholar] [CrossRef] [Green Version]
  153. Zaretsky, A.G.; Engiles, J.; Hunter, C.A. Infection-induced changes in hematopoiesis. J. Immunol. 2013, 192, 27–33. [Google Scholar] [CrossRef] [Green Version]
  154. Ueda, Y.; Yang, K.; Foster, S.J.; Kondo, M.; Kelsoe, G. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J. Exp. Med. 2004, 199, 47–58. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Kahn, R.; Schmidt, T.; Golestani, K.; Mossberg, A.; Gullstrand, B.; Bengtsson, A.A.; Kahn, F. Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19. J. Leukoc. Biol. 2020, 109, 115–120. [Google Scholar] [CrossRef]
  156. Mahanty, S.; Hutchinson, K.; Agarwal, S.; McRae, M.; Rollin, P.; Pulendran, B. Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and lassa viruses. J. Immunol. 2003, 170, 2797–2801. [Google Scholar] [CrossRef] [Green Version]
  157. Lubaki, N.M.; Ilinykh, P.; Pietzsch, C.; Tigabu, B.; Freiberg, A.N.; Koup, R.A.; Bukreyev, A. The lack of maturation of ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 2013, 87, 7471–7485. [Google Scholar] [CrossRef] [Green Version]
  158. Lubaki, N.M.; Younan, P.; Santos, R.I.; Meyer, M.; Iampietro, M.; Koup, R.A.; Bukreyev, A. The Ebola interferon inhibiting domains attenuate and dysregulate cell-mediated immune responses. PLoS Pathog. 2016, 12, e1006031. [Google Scholar] [CrossRef] [PubMed]
  159. Yao, X.H.; Li, T.Y.; He, Z.C.; Ping, Y.F.; Liu, H.W.; Yu, S.C.; Mou, H.M.; Wang, L.H.; Zhang, H.R.; Fu, W.J.; et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020, 49, 411–417. [Google Scholar]
  160. Jafarzadeh, A.; Jafarzadeh, S.; Nozari, P.; Mokhtari, P.; Nemati, M. Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms. Scand. J. Immunol. 2020, 93, e12967. [Google Scholar] [CrossRef]
  161. Janossy, G.P.A.; Bofill, M.; Weber, J.; McLaughlin, J.E.; Ornstein, M.; Ivory, K.; Harris, J.R.; Favrot, M.; Macdonald-Burns, D.C. An immunohistological approach to persistent lymphadenopathy and its relevance to AIDS. Clin. Exp. Immunol. 1985, 59, 257–266. [Google Scholar]
  162. Chen, L.; Flies, D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013, 13, 227–242. [Google Scholar] [CrossRef]
  163. Jubel, J.M.; Barbati, Z.R.; Burger, C.; Wirtz, D.C.; Schildberg, F.A. The role of PD-1 in acute and chronic infection. Front. Immunol. 2020, 11, 487. [Google Scholar] [CrossRef] [Green Version]
  164. Fischer, K.; Hoffmann, P.; Völkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; et al. Inhibitory effect of tumor cell—Derived lactic acid on human T cells. Blood 2007, 109, 3812–3819. [Google Scholar] [CrossRef]
  165. Peng, Y.D.; Meng, K.; Guan, H.Q.; Leng, L.; Zhu, R.R.; Wang, B.Y.; He, M.A.; Cheng, L.X.; Huang, K.; Zeng, Q.T. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi 2020, 48, E004. [Google Scholar]
  166. Paliogiannis, P.; Zinellu, A. Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis. Liver Int. 2020, 40, 1787–1788. [Google Scholar] [CrossRef]
  167. Malik, P.; Patel, U.; Mehta, D.; Patel, N.; Kelkar, R.; Akrmah, M.; Gabrilove, J.L.; Sacks, H. Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis. BMJ Evid.-Based Med. 2020, 26, 107–108. [Google Scholar] [CrossRef] [PubMed]
  168. Robertson, A.M.G.; Bird, C.C.; Waddell, A.W.; Currie, A.R. Morphological aspects of glucocorticoid-induced cell death in human lymphoblastoid cells. J. Pathol. 1978, 126, 181–187. [Google Scholar] [CrossRef] [PubMed]
  169. Fauci, A.S.; Dale, D.C.; Balow, J.E. Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann. Intern. Med. 1976, 84, 304–315. [Google Scholar] [CrossRef] [PubMed]
  170. Panesar, N.S.; Lam, C.W.K.; Chan, M.H.M.; Wong, C.K.; Sung, J.J.Y. Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol. Eur. J. Clin. Investig. 2004, 34, 382–384. [Google Scholar] [CrossRef]
  171. Leroy, E.M.; Baize, S.; Debre, P.; Lansoud-Soukate, J.; Mavoungou, E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 2001, 124, 453–460. [Google Scholar] [CrossRef]
  172. Lalueza, A.; Folgueira, D.; Díaz-Pedroche, C.; Hernández-Jiménez, P.; Ayuso, B.; Castillo, C.; Laureiro, J.; Trujillo, H.; Torres, M.; Lumbreras, C. Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome. Infect. Dis. 2019, 51, 543–546. [Google Scholar] [CrossRef]
  173. Fathi, N.; Rezaei, N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol. Int. 2020, 44, 1792–1797. [Google Scholar] [CrossRef]
  174. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensiv. Care Med. 2020, 46, 846–848. [Google Scholar] [CrossRef] [Green Version]
  175. Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-lefted, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481. [Google Scholar] [CrossRef] [Green Version]
  176. Okur, M.; Erbey, F.; Yazicioglu, O.; Celik, A.; Tukenmez, B.; Sunnetcioglu, M.; Gassaloglu, M.; Acar, M.N.; Kaya, A. H1N1 influenza a virus related pneumonia and respiratory failure. Indian J. Virol. 2013, 24, 85–89. [Google Scholar] [CrossRef] [Green Version]
  177. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422. [Google Scholar] [CrossRef]
  178. Pedersen, N.C.; Eckstrand, C.; Liu, H.; Leutenegger, C.; Murphy, B. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Veter. Microbiol. 2014, 175, 157–166. [Google Scholar] [CrossRef]
  179. Abrantes, J.; Van Der Loo, W.; Le Pendu, J.; Esteves, P.J. Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): A review. Veter. Res. 2012, 43, 12. [Google Scholar] [CrossRef] [Green Version]
  180. Masur, H. Recurring and emerging questions related to management of HIV-related opportunistic infections. Top. Antivir. Med. 2018, 26, 79–84. [Google Scholar]
  181. Ranganathan, K.; Umadevi, K.M.R. Common oral opportunistic infections in Human immunodeficiency virus infection/Acquired Immunodeficiency Syndrome: Changing epidemiology; diagnostic criteria and methods; management protocols. Periodontology 2019, 80, 177–188. [Google Scholar] [CrossRef] [PubMed]
  182. Wang, F.; Hou, H.; Luo, Y.; Tang, G.; Wu, S.; Huang, M.; Liu, W.; Zhu, Y.; Lin, Q.; Mao, L.; et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020, 5, e137799. [Google Scholar] [CrossRef] [PubMed]
  183. Pasero, D.; Sanna, S.; Liperi, C.; Piredda, D.; Branca, G.P.; Casadio, L.; Simeo, R.; Buselli, A.; Rizzo, D.; Bussu, F.; et al. A challenging complication following SARS-CoV-2 infection: A case of pulmonary mucormycosis. Infection 2020, 8, 1–6. [Google Scholar] [CrossRef]
Viruses 13 01876 g001 550
Figure 1. The underlying mechanisms of lymphopenia caused by viral infections.
Figure 1. The underlying mechanisms of lymphopenia caused by viral infections.
Viruses 13 01876 g001
Table
Table 1. Lymphopenia caused by viral infections and the possible mechanisms involved.
Table 1. Lymphopenia caused by viral infections and the possible mechanisms involved.
FamilySpeciesLymphocyte SubsetsPercentage CasesPossible MechanismsReference
RNACoronaviridaeSARS-CoV-2CD8+ T cells, CD4+ T cells, B cells, NK cells85% of the severe COVID-19 patientscell death
cytokines
lymphopoiesis
trafficking
co-inhibitory molecules
metabolic disorders		[5,14,15,16,17,18,19,20,21,22]
Middle east respiratory syndrome coronavirus (MERS-CoV)T cells34% of the MERS-CoV patientscell death
cytokines
lymphopoiesis
trafficking		[23,24,25,26]
Severe acute respiratory syndrome coronavirus (SARS-CoV)CD4+ T cells, CD8+ T cells, B cells, NK cells 90–100% patients in the acute phase of SARS patientscell death
cytokines
lymphopoiesis
trafficking
glucocorticoids		[27,28,29,30,31,32]
Feline infectious peritonitis virus (FIPV)CD4+ T cells, CD8+ T cells, B cells, NK cells77% of FIPV infected-catscell death
cytokines		[33,34,35,36]
Canine coronavirus
(CCoV)		Lymphocytesunknownunknown[37]
Equine coronavirus (ECoV)Lymphocytes81% of ECoV infected-horsesunknown[38]
RetroviridaeHIVCD4+ T cells49.17–65.2% of AIDS patientscell death
cytokines
lymphopoiesis
trafficking
co-inhibitory molecules		[39,40,41,42,43,44,45,46,47]
Simian immunodeficiency virus (SIV)CD4+ T cellsunknowncell death
trafficking		[48,49,50]
Bovine leukemia virus (BLV)B cellsunknownunknown[51]
FiloviridaeEBOVCD4+ T cells, CD8+ T cells, NK cellsunknowncell death
cytokines
trafficking
co-inhibitory molecules		[13,52,53,54,55,56]
Marburg virus (MARV)T cells, B cells, NK cellsunknowncytokines
metabolic disorders		[57,58,59]
Bundibugyo virus (BDBV)Lymphocytesunknowncytokines[60]
OrthomyxoviridaeInfluenza A virus (IAV),
IAV H5N1
IAV H7N9
IAV H1N1
IAV H5N6		CD4+ T cells, CD8+ T cells, B cells, NK cellsunknowncell death
cytokines
lymphopoiesis
trafficking
co-inhibitory molecules		[61,62,63,64,65,66]
ParamyxoviridaeMeasles virus (MV)CD4+ T cells, CD8+ T cells, B cellsunknowncell death
lymphopoiesis		[67,68]
Human parainfluenza virus type 3 (HPIV3)CD4+ T cells, CD8+ T cells, B cellsunknownunknown[69]
Canine distemper virus (CDV)CD4+ T cells, CD8+ T cells, B cellsunknowncell death
lymphopoiesis		[70,71,72]
Peste des petits ruminants virus (PPRV)Lymphocytesunknownunknown[73,74]
PneumoviridaeRespiratory syncytial virus (RSV)CD4+ T cells, CD8+ T cellsunknowncell death
cytokines
co-inhibitory molecules
metabolic disorders		[75,76,77,78]
ArteriviridaePorcine reproductive and respiratory syndrome virus (PRRSV)T cells, B cellsunknowncell death
cytokines
lymphopoiesis		[79,80]
PicornaviridaeFoot-and-mouth disease virus (FMDV)CD4+ T cells, CD8+ T cells, B cellsunknowncell death
cytokines
trafficking		[81,82,83,84,85]
Seneca Valley virus (SVV)B cellsunknowncell death[86]
FlaviviridaeClassical swine fever virus (CSFV)CD4+ T cells, CD8+ T cells, B cellsunknowncell death
cytokines
lymphopoiesis
co-inhibitory molecules		[87,88,89,90]
Hepatitis C virus (HCV)T cells6% of HCV-infected patients with acute exacerbationcell death
co-inhibitory molecules		[91,92]
Border disease virus (BDV)Lymphocytesunknownunknown[93]
Dengue Virus (DENV)Lymphocytes91.7% of DENV-infected patientsunknown[94]
West Nile virus (WNV)Lymphocytesunknownunknown[95]
Bovine viral diarrhoea virus (BVDV)CD4+ T cells, CD8+ T cells,unknowncell death
lymphopoiesis
co-inhibitory molecules		[96]
CaliciviridaeHuman norovirus (HNoV)T cells, B cellsunknowncytokines
trafficking		[97,98]
Rabbit haemorrhagic disease virus (RHDV) Lymphocytesunknowncell death[99]
Feline calicivirus (FCV)Lymphocytesunknownunknown[100,101]
ArenaviridaeLymphocytic choriomeningitis virus (LCMV)T cells, NK cellsunknownunknown[102]
TogaviridaeChikungunya virus (CHIKV)Lymphocytesunknownunknown[103]
DNAAsfarviridaeAfrican swine fever virus (ASFV)Lymphocytesunknowncell death[104]
CircoviridaePorcine circovirus type 2 (PCV-2)CD3+CD4+CD8+ T cells, CD3+CD4+CD8- T cells, CD3+CD4-CD8+ T cells, CD3+CD4-CD8- T cells, B cells, NK cellsunknownunknown[105]
HerpesviridaeCytomegalovirus (CMV)CD4+ T cells, CD8+ T cells, NK cells unknownunknown[106]
Marek’s disease virus (MDV)B cellsunknownunknown[107]
AlphaherpesvirinaeHerpes simplex virus (HSV)Lymphocytesunknownunknown[108]
ParvoviridaeFeline parvovirus (FPV)Lymphocytesunknownunknown[109]
Canine parvovirus (CPV)Lymphocytesunknownunknown[110]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Guo, Z.; Zhang, Z.; Prajapati, M.; Li, Y. Lymphopenia Caused by Virus Infections and the Mechanisms Beyond. Viruses 2021, 13, 1876. https://0-doi-org.brum.beds.ac.uk/10.3390/v13091876

AMA Style

Guo Z, Zhang Z, Prajapati M, Li Y. Lymphopenia Caused by Virus Infections and the Mechanisms Beyond. Viruses. 2021; 13(9):1876. https://0-doi-org.brum.beds.ac.uk/10.3390/v13091876

Chicago/Turabian Style

Guo, Zijing, Zhidong Zhang, Meera Prajapati, and Yanmin Li. 2021. "Lymphopenia Caused by Virus Infections and the Mechanisms Beyond" Viruses 13, no. 9: 1876. https://0-doi-org.brum.beds.ac.uk/10.3390/v13091876

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop